




We are a leading European small molecule contract research and manufacturing organization that has been a trusted global partner for biotech and pharma companies for over 30 years.

About us
We are a leading European small molecule contract research and manufacturing organization that has been a trusted global partner for biotech and pharma companies for over 30 years.
Symeres is the leading mid-sized European Contract Research Organization for your drug discovery and development needs. With over 500 scientists at six locations (Groningen, Nijmegen, & Weert in the Netherlands, Prague in the Czech Republic, Oulu in Finland and Södertälje in Sweden), we offer best-in-class solutions for drug discovery and drug development for small molecules and beyond. Our services span from early-stage hit finding all the way to the delivery of your early clinical drug substance API. We blend a deep scientific knowledge base with creativity to deliver the quality results your project needs. We Make Molecules Matter. Together.
Shortline Purple

Why work with us?
Symeres offers synthetic and analytical services, mainly in the field of organic and medicinal chemistry
Shortline White
- World-class expertise in discovery and development chemistry
- >30 years track record of successful project progression for our clients
- High staff retention gives you highly experienced teams
- Creative and adaptive problem-solving
- Excellence in communication
- Trusted partner network for additional platforms
- From hit finding to clinical supply under one roof
Hexa line white

Latest news
Stay updated on the most recent developments in Symeres
Shortline Purple

Symeres acquires Massachusetts-based Organix Inc., adding lipids expertise and creating a strategic foothold in the US market
We are happy and proud to announce the acquisition of Organix, a US-based provider of high-quality […]

Symeres’ daughter company Admescope welcomes Leah Haydock
Admescope, part of the Symeres family, has provided tailor-made ADME-Tox services to biotech and pharma companies […]